Sodium Glucose Cotransporter 2 Inhibition in the Diabetic Kidney

An Update

Aleksandra Novikov; Volker Vallon


Curr Opin Nephrol Hypertens. 2016;25(1):50-58. 

In This Article

Effects of Sodium Glucose Cotransporter 2 Inhibition Beyond the Reno–Cardiovascular System

SGLT2 inhibition is a chronic therapy and its effects on other clinical conditions are of great interest. In this regard, it was reported that glycemic control by SGLT2 inhibition for 10 weeks ameliorated cognitive dysfunction in obese T2DM mice.[49] Moreover, SGLT2 expression was detected in human pancreatic and prostate adenocarcinomas, and SGLT2 inhibitors blocked glucose uptake and reduced tumor growth and survival in a xenograft model of pancreatic cancer. Thus, imaging of functional SGLT2 by PET may help to diagnose and stage pancreatic and prostate cancers, and SGLT2 inhibitors may serve for cancer therapy.[50]